| DrugRepV_0011 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Zika virus | GZ01, a recent Asian lineage | NA | Plaque assay | No significant effect (45 %) | Approved | 29033372 |
| DrugRepV_0017 | Mibefradil | Cardiovascular agents | Angina | High blood pressure | Zika virus | GZ01, a recent Asian lineage | NA | Plaque assay | No significant effect (0 %) | Investigational, Withdrawn | 29033372 |
| DrugRepV_0018 | Fluvastatin | Cardiovascular agents | Cardiovascular disease (Coronary heart disease (CHD)) | Zika virus | GZ01, a recent Asian lineage | NA | Plaque assay | Increase (110 %) | Approved | 29033372 |
| DrugRepV_0215 | Ouabain | Cardiovascular agents | Atrial fibrillation and flutter | Heart failure | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (3.48 ± 0.21 Ct) | Approved | 27801778 |
| DrugRepV_0216 | Ouabain | Cardiovascular agents | Atrial fibrillation and flutter | Heart failure | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Increase (?3.73 ± 4.88 Ct) | Approved | 27801778 |
| DrugRepV_0251 | Ouabain | Cardiovascular agents | Atrial fibrillation and flutter | Heart failure | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (0.33 ± 0.35 Ct) | Approved | 27801778 |
| DrugRepV_0319 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0320 | Procainamide | Cardiovascular agents | Ventricular arrhythmias | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0328 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0340 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus | NA | Renilla luciferase assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0341 | Procainamide | Cardiovascular agents | Ventricular arrhythmias | Ebola virus | Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus | NA | Renilla luciferase assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0348 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus | NA | Renilla luciferase assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0357 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | Ebola Zaire | NA | Survival assay | Increase | Approved | 27622822 |
| DrugRepV_0368 | Amlodipine Besylate | Cardiovascular agents | Hypertension and chronic stable angina | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0379 | Deslanoside | Cardiovascular agents | Congestive cardiac insufficiency, arrhythmias and heart failure | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0381 | Digitoxin | Cardiovascular agents | Cardiac insufficiency, arrhythmias and heart failure | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0382 | Digoxin | Cardiovascular agents | Cardiac insufficiency, arrhythmias and heart failure | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0386 | Fluvastatin | Cardiovascular agents | Cardiovascular disease (Coronary heart disease (CHD)) | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0387 | Guanethidine Monosulfate | Cardiovascular agents | Hypertension | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0401 | Perhexiline Maleate | Cardiovascular agents | Angina pectoris | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0426 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0443 | Simvastatin | Cardiovascular agents | Hypercholesterolemia | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0444 | Strophanthin | Cardiovascular agents | Atrial fibrillation | Flutter | Heart failure | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0453 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0471 | Strophanthin | Cardiovascular agents | Atrial fibrillation | Flutter | Heart failure | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0482 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0500 | Simvastatin | Cardiovascular agents | Hypercholesterolemia | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0501 | Strophanthin | Cardiovascular agents | Atrial fibrillation | Flutter | Heart failure | Ebola virus | EBOV-VLP | NA | Flow cytometry | No significant effect | Approved | 26041706 |
| DrugRepV_0507 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | ma-EBOV | NA | Survival assay | Increase | Approved, Withdrawn | 26041706 |
| DrugRepV_0509 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | EBOV/Kik | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0510 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | SUDV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0511 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | MARV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0512 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | RAVV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0525 | Digoxin | Cardiovascular agents | Cardiac insufficiency, arrhythmias and heart failure | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0530 | Dronedarone | Cardiovascular agents | Arrhythmia | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0540 | Propafenone | Cardiovascular agents | Arrhythmia | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0542 | Deslanoside | Cardiovascular agents | Arrhythmia | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0557 | Mibefradil | Cardiovascular agents | Angina | High blood pressure | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Investigational, Withdrawn | 26038505 |
| DrugRepV_0563 | Aprindine | Cardiovascular agents | Arrhythmia | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0605 | Amlodipine | Cardiovascular agents | Hypertension | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (61 %) | Approved | 23577127 |
| DrugRepV_0624 | Penbutolol | Cardiovascular agents | Arterial hypertension | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (67 %) | Approved, Investigational | 23577127 |
| DrugRepV_0644 | Amlodipine | Cardiovascular agents | Hypertension | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (93 %) | Approved | 23577127 |
| DrugRepV_0663 | Penbutolol | Cardiovascular agents | Arterial hypertension | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (81 %) | Approved, Investigational | 23577127 |
| DrugRepV_0668 | Amlodipine | Cardiovascular agents | Hypertension | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (93 %) | Approved | 23577127 |
| DrugRepV_0687 | Penbutolol | Cardiovascular agents | Arterial hypertension | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (98 %) | Approved, Investigational | 23577127 |
| DrugRepV_0729 | Amlodipine | Cardiovascular agents | Hypertension | Ebola virus | ma-EBOV | NA | NA | No significant effect | Approved | 23577127 |
| DrugRepV_0731 | Penbutolol | Cardiovascular agents | Arterial hypertension | Ebola virus | ma-EBOV | NA | NA | No significant effect | Approved, Investigational | 23577127 |
| DrugRepV_0761 | Digoxin | Cardiovascular agents | Cardiac insufficiency, arrhythmias and heart failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (100 %) | Approved | 27476412 |
| DrugRepV_0787 | Nebivolol Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (72.455 %) | Approved, Investigational | 27476412 |
| DrugRepV_0797 | Prazosin Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (79.755 %) | Approved | 27476412 |
| DrugRepV_0798 | Tolvaptan | Cardiovascular agents | Hyponatremia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (71.575 %) | Approved | 27476412 |
| DrugRepV_0800 | Eplerenone | Cardiovascular agents | Left ventricular systolic dysfunction | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (66.435 %) | Approved | 27476412 |
| DrugRepV_0818 | Moexipril Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.935 %) | Approved | 27476412 |
| DrugRepV_0825 | Pitavastatin Calcium | Cardiovascular agents | Dyslipidemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (62.655 %) | Approved | 27476412 |
| DrugRepV_0828 | Irbesartan | Cardiovascular agents | Hypertension | Diabetic nephropathy | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (58.84 %) | Approved, Investigational | 27476412 |
| DrugRepV_0830 | Triamterene | Cardiovascular agents | Edema associated with congestive heart failure | Cirrhosis of the liver | Nephrotic syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (61.03 %) | Approved | 27476412 |
| DrugRepV_0841 | Pravastatin Sodium | Cardiovascular agents | Hypercholesterolemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.5 %) | Approved | 27476412 |
| DrugRepV_0854 | Metaraminol Bitartrate | Cardiovascular agents | Hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.365 %) | Approved, Investigational | 27476412 |
| DrugRepV_0857 | Atorvastatin Calcium | Cardiovascular agents | Coronary heart disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (61.57 %) | Approved | 27476412 |
| DrugRepV_0877 | Simvastatin | Cardiovascular agents | Hypercholesterolemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (57.405 %) | Approved | 27476412 |
| DrugRepV_0889 | Fluvastatin Sodium | Cardiovascular agents | Cardiovascular disease (Coronary heart disease (CHD)) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.69 %) | Approved | 27476412 |
| DrugRepV_0893 | Perindopril Erbumine | Cardiovascular agents | Hypertension | Congestive heart failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.56 %) | Approved | 27476412 |
| DrugRepV_0897 | Quinidine Hydrochloride Hydrate | Cardiovascular agents | Ventricular pre-excitation | Cardiac dysrhythmias | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (53.385 %) | Approved, Investigational | 27476412 |
| DrugRepV_0905 | Lovastatin | Cardiovascular agents | Atherosclerotic vascular disease | Hypercholesterolemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (59.375 %) | Approved, Investigational | 27476412 |
| DrugRepV_0913 | Ambrisentan | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.165 %) | Approved | 27476412 |
| DrugRepV_0936 | Chlorthalidone | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.405 %) | Approved | 27476412 |
| DrugRepV_0948 | Acebutolol Hydrochloride | Cardiovascular agents | Hypertension and ventricular premature beats | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.335 %) | Approved | 27476412 |
| DrugRepV_0949 | Procainamide Hydrochloride | Cardiovascular agents | Ventricular arrhythmias | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.96 %) | Approved | 27476412 |
| DrugRepV_0953 | Valsartan | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.425 %) | Approved | 27476412 |
| DrugRepV_0966 | Chlorothiazide | Cardiovascular agents | Edema associated with congestive heart failure, hepatic cirrhosis and hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.72 %) | Approved | 27476412 |
| DrugRepV_0999 | Dofetilide | Cardiovascular agents | Atrial flutter | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (56.755 %) | Approved | 27476412 |
| DrugRepV_1003 | Carvedilol | Cardiovascular agents | Congestive heart failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.625 %) | Approved | 27476412 |
| DrugRepV_1009 | Olmesartan | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.095 %) | Approved, Investigational | 27476412 |
| DrugRepV_1010 | Lidocaine Hydrochloride Hydrate | Cardiovascular agents | Anesthesia | Ventricular arrhythmias | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.62 %) | Approved, Vet approved | 27476412 |
| DrugRepV_1016 | Spironolactone | Cardiovascular agents | Heart failure | Hyperaldosteronism | Adrenal hyperplasia | Hypertension | Nephrotic syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.965 %) | Approved | 27476412 |
| DrugRepV_1027 | Ibutilide Fumarate | Cardiovascular agents | Atrial flutter | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.475 %) | Approved | 27476412 |
| DrugRepV_1028 | Guanabenz Acetate | Cardiovascular agents | High blood pressure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.815 %) | Approved | 27476412 |
| DrugRepV_1044 | Clonidine Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.37 %) | Approved | 27476412 |
| DrugRepV_1047 | Ezetimibe | Cardiovascular agents | Hyperlipidemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.62 %) | Approved | 27476412 |
| DrugRepV_1060 | Amiloride Hydrochloride Dihydrate | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.595 %) | Approved | 27476412 |
| DrugRepV_1068 | Norepinephrine Bitartrate Monohydrate | Cardiovascular agents | Vasodilatory shock states such as septic shock and neurogenic shock | Vasopressor medication for patients with critical hypotension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.87 %) | Approved | 27476412 |
| DrugRepV_1077 | Rosuvastatin Calcium | Cardiovascular agents | Hyperlipidemia | Dyslipidemia | Hypertriglyceridemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.215 %) | Approved | 27476412 |
| DrugRepV_1081 | Labetalol Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.74 %) | Approved | 27476412 |
| DrugRepV_1088 | Methyclothiazide | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.82 %) | Approved | 27476412 |
| DrugRepV_1110 | Pentoxifylline | Cardiovascular agents | Chronic occlusive arterial disease of the limbs | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.155 %) | Approved, Investigational | 27476412 |
| DrugRepV_1117 | Losartan Potassium | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.79 %) | Approved | 27476412 |
| DrugRepV_1120 | Nisoldipine | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (53.255 %) | Approved | 27476412 |
| DrugRepV_1121 | Dobutamine Hydrochloride | Cardiovascular agents | Cardiovascular disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.705 %) | Approved | 27476412 |
| DrugRepV_1133 | Candesartan | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.62 %) | Experimental | 27476412 |
| DrugRepV_1134 | Disopyramide | Cardiovascular agents | Ventricular tachycardia and arrhythmias | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.605 %) | Approved | 27476412 |
| DrugRepV_1136 | Sotalol Hydrochloride | Cardiovascular agents | Atrial flutter | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.965 %) | Approved | 27476412 |
| DrugRepV_1137 | Fenofibrate | Cardiovascular agents | Hypercholesterolemia | Dyslipidemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.755 %) | Approved | 27476412 |
| DrugRepV_1141 | Torsemide | Cardiovascular agents | Edema and hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.19 %) | Approved | 27476412 |
| DrugRepV_1143 | Metoprolol Tartrate | Cardiovascular agents | Angina | Heart failure | Myocardial infarction | Atrial fibrillation | Atrial flutter | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.545 %) | Approved, Investigational | 27476412 |
| DrugRepV_1154 | Quinapril Hydrochloride | Cardiovascular agents | Hypertension | Congestive heart failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (53.015 %) | Approved, Investigational | 27476412 |
| DrugRepV_1156 | Metolazone | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.57 %) | Approved | 27476412 |
| DrugRepV_1176 | Trandolapril | Cardiovascular agents | Hypertension and Congestive heart failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.025 %) | Approved | 27476412 |
| DrugRepV_1178 | Phenoxybenzamine Hydrochloride | Cardiovascular agents | Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.895 %) | Approved | 27476412 |
| DrugRepV_1179 | Amiodarone Hydrochloride | Cardiovascular agents | Anginal and Arrhythmia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.055 %) | Approved | 27476412 |
| DrugRepV_1185 | Isosorbide Dinitrate | Cardiovascular agents | Angina pectoris (Coronary artery disease) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.66 %) | Approved, Investigational | 27476412 |
| DrugRepV_1190 | Ranolazine Dihydrochloride | Cardiovascular agents | Chronic angina | Ventricular tachycardia | Acute coronary syndrome | Microvascular coronary dysfunction | Arrhythmia | Glycemic control | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.88 %) | Approved | 27476412 |
| DrugRepV_1208 | Regadenoson | Cardiovascular agents | Myocardial perfusion imaging (MPI) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.46 %) | Approved | 27476412 |
| DrugRepV_1222 | Betaxolol Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.605 %) | Approved | 27476412 |
| DrugRepV_1226 | Pindolol | Cardiovascular agents | Hypertension | Edema | Ventricular tachycardias | Atrial fibrillation | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.37 %) | Approved, Investigational | 27476412 |
| DrugRepV_1236 | Phentolamine Hydrochloride | Cardiovascular agents | Pheochromocytoma | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.465 %) | Approved | 27476412 |
| DrugRepV_1242 | Captopril | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.42 %) | Approved | 27476412 |
| DrugRepV_1259 | Nicardipine Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.09 %) | Approved, Investigational | 27476412 |
| DrugRepV_1270 | Flecainide Acetate | Cardiovascular agents | Arrhythmia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.52 %) | Approved, Withdrawn | 27476412 |
| DrugRepV_1272 | Milrinone | Cardiovascular agents | Cardiotonic agent | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.26 %) | Approved | 27476412 |
| DrugRepV_1279 | Dopamine Hydrochloride | Cardiovascular agents | Arrythmias and arterial hypotension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.74 %) | Approved | 27476412 |
| DrugRepV_1304 | Ramipril | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.37 %) | Approved | 27476412 |
| DrugRepV_1305 | Bisoprolol Fumarate | Cardiovascular agents | Cardiovascular disease, angina pectoris and myocardial infarction | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.34 %) | Approved | 27476412 |
| DrugRepV_1314 | Gemfibrozil | Cardiovascular agents | Hyperlipidemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.965 %) | Approved | 27476412 |
| DrugRepV_1317 | Esmolol | Cardiovascular agents | Cardiovascular disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.035 %) | Approved | 27476412 |
| DrugRepV_1323 | Eprosartan Mesylate | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.265 %) | Approved | 27476412 |
| DrugRepV_1330 | Methyldopa Sesquihydrate | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.48 %) | Approved | 27476412 |
| DrugRepV_1331 | Propafenone Hydrochloride | Cardiovascular agents | Paroxysmal atrial fibrillation/flutter | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.065 %) | Approved | 27476412 |
| DrugRepV_1342 | Hydroflumethiazide | Cardiovascular agents | Edema | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.285 %) | Approved, Investigational | 27476412 |
| DrugRepV_1360 | Bumetanide | Cardiovascular agents | Edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.355 %) | Approved | 27476412 |
| DrugRepV_1361 | Fenoldopam Mesylate | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.23 %) | Approved | 27476412 |
| DrugRepV_1385 | Enalapril | Cardiovascular agents | Hypertension and Diabetic nephropathies | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.605 %) | Approved | 27476412 |
| DrugRepV_1387 | Indapamide | Cardiovascular agents | Hypertension | Edema | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.8 %) | Approved | 27476412 |
| DrugRepV_1389 | Diazoxide | Cardiovascular agents | Hypertension, hyperinsulinemic and hypoglycemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.04 %) | Approved | 27476412 |
| DrugRepV_1390 | Mexiletine Hydrochloride | Cardiovascular agents | Ventricular tachycardia | Symptomatic premature ventricular beats | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.255 %) | Approved, Investigational | 27476412 |
| DrugRepV_1397 | Atenolol | Cardiovascular agents | Hypertension and angina pectoris | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.835 %) | Approved | 27476412 |
| DrugRepV_1407 | Amrinone | Cardiovascular agents | Congestive heart failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.125 %) | Approved | 27476412 |
| DrugRepV_1410 | Hydralazine Hydrochloride | Cardiovascular agents | Hypertension | Congestive heart failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.67 %) | Approved | 27476412 |
| DrugRepV_1412 | Nifedipine | Cardiovascular agents | Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.03 %) | Approved | 27476412 |
| DrugRepV_1414 | Fosinopril Sodium | Cardiovascular agents | Hypertension | Congestive heart failure | Renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.225 %) | Approved | 27476412 |
| DrugRepV_1420 | Nadolol | Cardiovascular agents | Arrhythmias | Angina pectoris | Hypertension | Migraine disorders | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.93 %) | Approved | 27476412 |
| DrugRepV_1427 | Furosemide | Cardiovascular agents | Edema and Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (40.555 %) | Approved, Vet approved | 27476412 |
| DrugRepV_1432 | Bendroflumethiazide | Cardiovascular agents | Familial hyperkalemia, hypertension, edema, and urinary tract disorders | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.345 %) | Approved | 27476412 |
| DrugRepV_1436 | Telmisartan | Cardiovascular agents | Hypertension | Type 2 diabetes mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.505 %) | Approved, Investigational | 27476412 |
| DrugRepV_1441 | Diltiazem Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.9 %) | Approved | 27476412 |
| DrugRepV_1442 | Lisinopril dihydrate | Cardiovascular agents | Hypertension | Congestive heart failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.825 %) | Approved, Investigational | 27476412 |
| DrugRepV_1445 | Ethacrynic Acid | Cardiovascular agents | Edema, hypertension and congestive heart failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.32 %) | Approved | 27476412 |
| DrugRepV_1453 | Verapamil Hydrochloride | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.75 %) | Approved | 27476412 |
| DrugRepV_1466 | Hydrochlorothiazide | Cardiovascular agents | High blood pressure | Edema | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (41.61 %) | Approved, Vet approved | 27476412 |
| DrugRepV_1467 | Bosentan | Cardiovascular agents | Pulmonary artery hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.61 %) | Approved | 27476412 |
| DrugRepV_1468 | Isradipine | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (38.02 %) | Approved, Investigational | 27476412 |
| DrugRepV_1470 | Enalaprilat Maleate | Cardiovascular agents | Hypertension and symptomatic congestive heart failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.67 %) | Approved | 27476412 |
| DrugRepV_1476 | Benazepril Hydrochloride | Cardiovascular agents | Hypertension, congestive heart failure and chronic renal failure | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (38.975 %) | Approved | 27476412 |
| DrugRepV_1483 | Adenosine | Cardiovascular agents | Arrhythmia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.51 %) | Approved | 27476412 |
| DrugRepV_1491 | Propranolol Hydrochloride | Cardiovascular agents | Migraine | Acute myocardial infarction | Arrhythmias | Angina pectoris | Hypertension | Hypertensive emergencies | Hyperthyroidism | Pheochromocytoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.09 %) | Approved, Investigational | 27476412 |
| DrugRepV_1500 | Doxazosin Mesylate | Cardiovascular agents | Hypertension and Hyperplasia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (38.835 %) | Approved | 27476412 |
| DrugRepV_1506 | Nimodipine | Cardiovascular agents | Subarachnoid hemorrhage (SAH) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (40.835 %) | Approved, Investigational | 27476412 |
| DrugRepV_1514 | Reserpine | Cardiovascular agents | Hypertension | Psychotic disorder | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (34.15 %) | Approved, Investigational | 27476412 |
| DrugRepV_1518 | Amlodipine | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (26.615 %) | Approved | 27476412 |
| DrugRepV_1531 | Felodipine | Cardiovascular agents | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (25.83 %) | Approved, Investigational | 27476412 |
| DrugRepV_1579 | Manidipine Dihydrochloride | Cardiovascular agents | Hypertension | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (63 %) | Approved, Investigational | 26217313 |
| DrugRepV_1624 | Imidapril | Cardiovascular agents | Autosomal dominant polycystic kidney disease (ADPKD) | Influenza virus | A/Anhui/01/2013 |  | Transcriptomic response-DEG | Decrease | Investigational | 24991006 |
| DrugRepV_1627 | Dobutamine | Cardiovascular agents | Myocardial infarction | Influenza virus | A/Anhui/01/2013 | | Transcriptomic response-DEG | Decrease | Approved | 24991006 |
| DrugRepV_1629 | Carteolol | Cardiovascular agents | Anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent | Influenza virus | A/Anhui/01/2013 | | Transcriptomic response-DEG | Decrease | Approved | 24991006 |
| DrugRepV_1630 | Candesartan cilexetil | Cardiovascular agents | Hypertension | Influenza virus | A/Anhui/01/2013 | | Transcriptomic response-DEG | Decrease | Approved | 24991006 |
| DrugRepV_1719 | Dalcetrapib | Cardiovascular agents | Acute Coronary Syndrome | Zika virus | MR766 | NA | Cell viability assay | Decrease (45.7 %) | Investigational | 27571349 |
| DrugRepV_1790 | Dalcetrapib | Cardiovascular agents | Acute Coronary Syndrome | Zika virus | MR766 | NA | Cell viability assay | Decrease | Investigational | 27571349 |
| DrugRepV_1861 | Dalcetrapib | Cardiovascular agents | Acute Coronary Syndrome | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1925 | Manidipine | Cardiovascular agents | Hypertension | Influenza virus | PR/8/34 | | Plaque assay | No significant effect (50 %) | Approved, Investigational | 29274844 |
| DrugRepV_1926 | Manidipine | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Plaque assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_1927 | Cilnidipine | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Plaque assay | Decrease (100 %) | Approved | 28814523 |
| DrugRepV_1928 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Plaque assay | Decrease (3 Logs) | Approved | 28814523 |
| DrugRepV_1931 | Manidipine | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Real-time PCR | Decrease (0 %) | Approved, Investigational | 28814523 |
| DrugRepV_1932 | Cilnidipine | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Real-time PCR | Decrease (0.01 %) | Approved | 28814523 |
| DrugRepV_1933 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Real-time PCR | Decrease (0.03 %) | Approved | 28814523 |
| DrugRepV_1936 | Manidipine | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Immunoflourescence assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_1937 | Cilnidipine | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Immunoflourescence assay | Decrease (100 %) | Approved | 28814523 |
| DrugRepV_1938 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Zika virus | H/PF/2013 | NA | Immunoflourescence assay | Decrease | Approved | 28814523 |
| DrugRepV_1966 | Lanatoside C | Cardiovascular agents | Arrhythmia | Chikungunya virus | NA | NA | Plaque assay | Decrease (38.66 %) | Experimental | 25251726 |
| DrugRepV_2020 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | Zaire strain-pEBOV | NA | Firefly luciferase assay | Decrease (50 %) | Approved, Investigational | 26585243 |
| DrugRepV_2047 | Cilnidipine | Cardiovascular agents | Hypertension | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (60 %) | Approved | 24841269 |
| DrugRepV_2049 | Manidipine | Cardiovascular agents | Hypertension | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved, Investigational | 24841269 |
| DrugRepV_2069 | Lacidipine | Cardiovascular agents | Hypertension | Lassa virus | LASVpv | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 29899092 |
| DrugRepV_2163 | Levosimendan | Cardiovascular agents | Chronic heart failure (CHF) | Heart disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (54.4775159 %) | Approved, Investigational | 27742486 |
| DrugRepV_2166 | Azilsartan Medoxomil | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (42.534615 %) | Approved | 27742486 |
| DrugRepV_2172 | Azilsartan | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (33.7555588 %) | Approved | 27742486 |
| DrugRepV_2173 | Candesartan cilexetil | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (19.4231062 %) | Approved | 27742486 |
| DrugRepV_2175 | Fluvastatin Sodium | Cardiovascular agents | Cardiovascular disease (Coronary heart disease (CHD)) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (18.5093019 %) | Approved | 27742486 |
| DrugRepV_2181 | Lovastatin | Cardiovascular agents | Atherosclerotic vascular disease | Hypercholesterolemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (14.1848079 %) | Approved, Investigational | 27742486 |
| DrugRepV_2193 | Fenofibrate | Cardiovascular agents | Hypercholesterolemia | Dyslipidemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.8996039 %) | Approved | 27742486 |
| DrugRepV_2211 | Ranolazine Dihydrochloride | Cardiovascular agents | Chronic angina | Ventricular tachycardia | Acute coronary syndrome | Microvascular coronary dysfunction | Arrhythmia | Glycemic control | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.80000539 %) | Approved | 27742486 |
| DrugRepV_2233 | Reserpine | Cardiovascular agents | Hypertension | Psychotic disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.9045194 %) | Approved, Investigational | 27742486 |
| DrugRepV_2239 | Acipimox | Cardiovascular agents | Hyperlipidemias | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.42097206 %) | Approved | 27742486 |
| DrugRepV_2256 | Captopril | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.73529808 %) | Approved | 27742486 |
| DrugRepV_2259 | Lidocaine | Cardiovascular agents | Anesthesia | Ventricular arrhythmias | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.70999199 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2266 | Nisoldipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.19489422 %) | Approved | 27742486 |
| DrugRepV_2267 | Conivaptan Hydrochloride | Cardiovascular agents | Hypervolemic hyponatremia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.13797577 %) | Approved | 27742486 |
| DrugRepV_2292 | Probucol | Cardiovascular agents | LDL and HDL cholesterol | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.54118117 %) | Approved, Investigational | 27742486 |
| DrugRepV_2305 | Sotalol | Cardiovascular agents | Atrial flutter | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.33498865 %) | Approved | 27742486 |
| DrugRepV_2308 | Urapidil Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.25520328 %) | Investigational | 27742486 |
| DrugRepV_2327 | Moxonidine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.70472644 %) | Approved, Investigational | 27742486 |
| DrugRepV_2344 | Doxazosin Mesylate | Cardiovascular agents | Hypertension and Hyperplasia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.283278 %) | Approved | 27742486 |
| DrugRepV_2356 | Metoprolol Tartrate | Cardiovascular agents | Angina | Heart failure | Myocardial infarction | Atrial fibrillation | Atrial flutter | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.12858015 %) | Approved, Investigational | 27742486 |
| DrugRepV_2363 | Clofibrate | Cardiovascular agents | Hyperlipoproteinemia type III | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.86775626 %) | Approved | 27742486 |
| DrugRepV_2367 | Buflomedil Hydrochloride | Cardiovascular agents | Claudication and peripheral arterial disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.79867437 %) | NA | 27742486 |
| DrugRepV_2374 | Enalaprilat Dihydrate | Cardiovascular Agents | Hypertension and symptomatic congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.61173617 %) | Approved | 27742486 |
| DrugRepV_2382 | Cleviprex | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.43173855 %) | Approved | 27742486 |
| DrugRepV_2389 | Temocapril Hydrochloride | Cardiovascular agents | Hypertension | Congestive heart failure | Diabetic nephropathy | Improvement of prognosis for coronary artery diseases | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.35963363 %) | Experimental, Investigational | 27742486 |
| DrugRepV_2391 | Clonidine Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.34543683 %) | Approved | 27742486 |
| DrugRepV_2394 | Nebivolol | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.30490861 %) | Approved, Investigational | 27742486 |
| DrugRepV_2396 | Trichlormethiazide | Cardiovascular agents | Oedema and Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.27400898 %) | Approved | 27742486 |
| DrugRepV_2405 | Nicorandil | Cardiovascular agents | Acute coronary syndromes | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.17516391 %) | Approved, Investigational | 27742486 |
| DrugRepV_2419 | Ranolazine | Cardiovascular agents | Chronic angina | Ventricular tachycardia | Acute coronary syndrome | Microvascular coronary dysfunction | Arrhythmia | Glycemic control | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.92187432 %) | Approved, Investigational | 27742486 |
| DrugRepV_2421 | Manidipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.86580948 %) | Approved, Investigational | 27742486 |
| DrugRepV_2425 | Quinapril Hydrochloride | Cardiovascular agents | Hypertension | Congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.78829028 %) | Approved, Investigational | 27742486 |
| DrugRepV_2446 | Moexipril Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.15869259 %) | Approved | 27742486 |
| DrugRepV_2452 | Bisoprolol | Cardiovascular agents | Cardiovascular disease, angina pectoris and myocardial infarction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.01316496 %) | Approved | 27742486 |
| DrugRepV_2462 | Propafenone | Cardiovascular agents | Arrhythmia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.83756587 %) | Approved | 27742486 |
| DrugRepV_2469 | Milrinone | Cardiovascular agents | Cardiotonic agent | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.70603205 %) | Approved | 27742486 |
| DrugRepV_2470 | Cilnidipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.67413581 %) | Approved | 27742486 |
| DrugRepV_2475 | Acadesine | Cardiovascular agents | Cardiac reperfusion injury, cardiovascular disorders, and coronary artery disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.50184624 %) | Approved | 27742486 |
| DrugRepV_2481 | Dopamine Hydrochloride | Cardiovascular agents | Arrythmias and arterial hypotension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.35461971 %) | Approved | 27742486 |
| DrugRepV_2500 | Olmesartan Medoxomil | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.09317819 %) | Approved, Investigational | 27742486 |
| DrugRepV_2503 | Isoprenaline Hydrochloride | Cardiovascular agents | Heart block | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.06631438 %) | Approved, Investigational | 27742486 |
| DrugRepV_2505 | Dofetilide | Cardiovascular agents | Arrhythmia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.03153927 %) | Approved | 27742486 |
| DrugRepV_2520 | Irbesartan | Cardiovascular agents | Hypertension | Diabetic nephropathy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.2498496 %) | Approved, Investigational | 27742486 |
| DrugRepV_2552 | Diltiazem Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.874358 %) | Approved | 27742486 |
| DrugRepV_2559 | Phentolamine Mesilate | Cardiovascular agents | Pheochromocytoma | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.022123 %) | Approved | 27742486 |
| DrugRepV_2560 | Cilazapril Monohydrate | Cardiovascular agents | Hypertension and heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.0262964 %) | Approved | 27742486 |
| DrugRepV_2573 | Nimodipine | Cardiovascular agents | Subarachnoid hemorrhage (SAH) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2547481 %) | Approved, Investigational | 27742486 |
| DrugRepV_2576 | Isradipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2706832 %) | Approved, Investigational | 27742486 |
| DrugRepV_2578 | Rosuvastatin Calcium | Cardiovascular agents | Hyperlipidemia | Dyslipidemia | Hypertriglyceridemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3486114 %) | Approved | 27742486 |
| DrugRepV_2592 | Bumetanide | Cardiovascular agents | Edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.4483238 %) | Approved | 27742486 |
| DrugRepV_2599 | Methyldopa | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5755527 %) | Approved | 27742486 |
| DrugRepV_2600 | Betaxolol Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5822028 %) | Approved | 27742486 |
| DrugRepV_2612 | Felodipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7151698 %) | Approved, Investigational | 27742486 |
| DrugRepV_2618 | Benazepril Hydrochloride | Cardiovascular agents | Hypertension, congestive heart failure and chronic renal failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7768175 %) | Approved | 27742486 |
| DrugRepV_2627 | Nitrendipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8300478 %) | Approved, Investigational | 27742486 |
| DrugRepV_2636 | Amiloride Hydrochloride Dihydrate | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.9573532 %) | Approved | 27742486 |
| DrugRepV_2641 | Phenoxybenzamine Hydrochloride | Cardiovascular agents | Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.0355134 %) | Approved | 27742486 |
| DrugRepV_2663 | Manidipine Dihydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3680473 %) | Approved, Investigational | 27742486 |
| DrugRepV_2666 | Candesartan | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3946995 %) | Approved | 27742486 |
| DrugRepV_2674 | Hydralazine Hydrochloride | Cardiovascular agents | Hypertension | Congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.4875991 %) | Approved | 27742486 |
| DrugRepV_2675 | Gemfibrozil | Cardiovascular agents | Hyperlipidemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5184325 %) | Approved | 27742486 |
| DrugRepV_2677 | Aliskiren Hemifumarate | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5377825 %) | Approved | 27742486 |
| DrugRepV_2678 | Amiloride Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5420556 %) | Approved | 27742486 |
| DrugRepV_2681 | Ramipril | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5841949 %) | Approved | 27742486 |
| DrugRepV_2708 | Lisinopril | Cardiovascular agents | Hypertension | Congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.0316803 %) | Approved, Investigational | 27742486 |
| DrugRepV_2711 | Enalapril Maleate | Cardiovascular agents | Hypertension and Diabetic nephropathies | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.1210281 %) | Approved | 27742486 |
| DrugRepV_2713 | Perindopril erbumine | Cardiovascular agents | Hypertension | Congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.1490604 %) | Approved | 27742486 |
| DrugRepV_2719 | Lacidipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.2613206 %) | Approved, Investigational | 27742486 |
| DrugRepV_2724 | Octopamine Hydrochloride | Cardiovascular agents | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.3569036 %) | NA | 27742486 |
| DrugRepV_2728 | Pravastatin Sodium | Cardiovascular agents | Hypercholesterolemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4229682 %) | Approved | 27742486 |
| DrugRepV_2730 | Amlodipine Besylate | Cardiovascular agents | Hypertension and chronic stable angina | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4244387 %) | Approved | 27742486 |
| DrugRepV_2735 | Ivabradine Hydrochloride | Cardiovascular agents | Angina pectoralis | Chronic heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.5395934 %) | Approved | 27742486 |
| DrugRepV_2748 | Dronedarone Hydrochloride | Cardiovascular agents | Arrhythmia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.8605968 %) | Approved | 27742486 |
| DrugRepV_2753 | Telmisartan | Cardiovascular agents | Hypertension | Type 2 diabetes mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.9984663 %) | Approved, Investigational | 27742486 |
| DrugRepV_2774 | Droxidopa | Cardiovascular agents | Parkinson's Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4482179 %) | Approved | 27742486 |
| DrugRepV_2786 | Indapamide | Cardiovascular agents | Hypertension | Edema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.6882509 %) | Approved | 27742486 |
| DrugRepV_2792 | Amlodipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.7826838 %) | Approved | 27742486 |
| DrugRepV_2794 | Torsemide | Cardiovascular agents | Edema and hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.8209892 %) | Approved | 27742486 |
| DrugRepV_2808 | Metolazone | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.2375608 %) | Approved | 27742486 |
| DrugRepV_2823 | Nifedipine | Cardiovascular agents | Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.6404656 %) | Approved | 27742486 |
| DrugRepV_2836 | Ezetimibe | Cardiovascular agents | Hyperlipidemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.124775 %) | Approved | 27742486 |
| DrugRepV_2840 | Valsartan | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.2598292 %) | Approved | 27742486 |
| DrugRepV_2844 | Eplerenone | Cardiovascular agents | Left ventricular systolic dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.3670777 %) | Approved | 27742486 |
| DrugRepV_2863 | Pitavastatin Calcium | Cardiovascular agents | Dyslipidemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.2349302 %) | Approved | 27742486 |
| DrugRepV_2868 | Furosemide | Cardiovascular agents | Edema and Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.3838268 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2872 | Tolvaptan | Cardiovascular agents | Hyponatremia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.7162491 %) | Approved | 27742486 |
| DrugRepV_2880 | Hydrochlorothiazide | Cardiovascular agents | High blood pressure | Edema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.2049254 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2885 | Carvedilol | Cardiovascular agents | Congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.3562769 %) | Approved | 27742486 |
| DrugRepV_2888 | Cinepazide Maleate | Cardiovascular agents | Ischemic Stroke | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.5219495 %) | Investigational | 27742486 |
| DrugRepV_2916 | Chlorothiazide | Cardiovascular agents | Edema associated with congestive heart failure, hepatic cirrhosis and hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-10.451156 %) | Approved | 27742486 |
| DrugRepV_2927 | Amiodarone Hydrochloride | Cardiovascular agents | Anginal and Arrhythmia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-12.235293 %) | Approved | 27742486 |
| DrugRepV_2930 | Nilvadipine | Cardiovascular agents | Angina | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-12.889881 %) | Approved | 27742486 |
| DrugRepV_2931 | Adenosine | Cardiovascular agents | Arrhythmia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-12.932123 %) | Approved | 27742486 |
| DrugRepV_3052 | Cerivastatin | Cardiovascular agents | Rhabdomyolysis | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (70 %) | Approved | 26752081 |
| DrugRepV_3065 | Cerivastatin | Cardiovascular agents | Rhabdomyolysis | Chikungunya virus | CHIKV-Rluc | NA | Renilla luciferase assay | No significant effect (10 %) | Approved | 26752081 |
| DrugRepV_3079 | Cerivastatin | Cardiovascular agents | Rhabdomyolysis | Chikungunya virus | CHIKV-Rluc | NA | Plaque assay | No significant effect (No significant effect Log) | Approved | 26752081 |
| DrugRepV_3285 | Prenylamine | Cardiovascular agents | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Withdrawn | 27177310 |
| DrugRepV_3286 | Felodipine | Cardiovascular agents | Hypertension | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational | 27177310 |
| DrugRepV_3566 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | EBOV/Mak | NA | Luminescence assay | Decrease (50 %) | Approved, Investigational | 30016444 |
| DrugRepV_3567 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | EBOV/Mak | NA | Luminescence assay | Decrease (50 %) | Approved, Investigational | 30016444 |
| DrugRepV_3568 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | EBOV/Mak | NA | Luminescence assay | Decrease (50 %) | Approved, Investigational | 30016444 |
| DrugRepV_3569 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | EBOV/May-GPA | NA | Luminescence assay | Decrease (50 %) | Approved, Investigational | 30016444 |
| DrugRepV_3570 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | EBOV/May-GPA | NA | Luminescence assay | Decrease (50 %) | Approved, Investigational | 30016444 |
| DrugRepV_3591 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Withdrawn | 30149038 |
| DrugRepV_3592 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3748 | Amiodarone Hydrochloride | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | 1976 | NA | Firefly luciferase assay | Decrease (50 %) | Approved | 25986249 |
| DrugRepV_3749 | Amiodarone Hydrochloride | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | 2014 | NA | Firefly luciferase assay | Decrease (50 %) | Approved | 25986249 |
| DrugRepV_3750 | Amiodarone Hydrochloride | Cardiovascular agents | Anginal and Arrhythmia | Lassa virus | NA | NA | Firefly luciferase assay | Decrease (50 %) | Approved | 25986249 |
| DrugRepV_4025 | Amlodipine Besylate | Cardiovascular agents | Hypertension and chronic stable angina | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4029 | Mibefradil | Cardiovascular agents | Angina | High blood pressure | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational, Withdrawn | 20668647 |
| DrugRepV_4030 | Nifedipine | Cardiovascular agents | Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4033 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4035 | Amiloride | Cardiovascular agents | Hypertension | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4040 | Amlodipine Besylate | Cardiovascular agents | Hypertension and chronic stable angina | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4044 | Mibefradil | Cardiovascular agents | Angina | High blood pressure | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational, Withdrawn | 20668647 |
| DrugRepV_4045 | Nifedipine | Cardiovascular agents | Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4048 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4050 | Amiloride | Cardiovascular agents | Hypertension | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4058 | Phenoxybenzamine | Cardiovascular agents | Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4067 | Phenoxybenzamine | Cardiovascular agents | Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4079 | Propranolol | Cardiovascular agents | Migraine | Acute myocardial infarction | Arrhythmias | Angina pectoris | Hypertension | Hypertensive emergencies | Hyperthyroidism | Pheochromocytoma | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational | 20668647 |
| DrugRepV_4087 | Propranolol | Cardiovascular agents | Migraine | Acute myocardial infarction | Arrhythmias | Angina pectoris | Hypertension | Hypertensive emergencies | Hyperthyroidism | Pheochromocytoma | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational | 20668647 |
| DrugRepV_4656 | Lovastatin | Cardiovascular agents | Atherosclerotic vascular disease | Hypercholesterolemia | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27909576 |
| DrugRepV_5262 | Epigallocatechin Gallate | Cardiovascular agents | Hypertension and Diabetic Nephropathy | Zika virus | MR766 | NA | Plaque assay | Decrease (4.3 x 104 Log) | Investigational | 28744282 |
| DrugRepV_5264 | Epigallocatechin Gallate | Cardiovascular agents | Hypertension and Diabetic Nephropathy | Zika virus | PA259459 | NA | Plaque assay | Decrease | Investigational | 28744282 |
| DrugRepV_5486 | Conivaptan | Cardiovascular agents | Hypervolemic hyponatremia | Zika virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational | 31786251 |
| DrugRepV_5488 | Candesartan cilexetil | Cardiovascular agents | Hypertension | Zika virus | PRVABC59 | NA | Cell viability assay | Decrease (50 %) | Approved | 31669333 |
| DrugRepV_5587 | Captopril | Cardiovascular agents | Hypertension | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5588 | Lisinopril | Cardiovascular agents | Hypertension | Congestive heart failure | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved, Investigational | 32353859 |
| DrugRepV_5748 | Manidipine | Cardiovascular agents | Hypertension | Dengue virus | DENV-2 replicon | | Luciferase reporter assay | Decrease (75 %) | Approved, Investigational | 28814523 |
| DrugRepV_5749 | Cilnidipine | Cardiovascular agents | Hypertension | Dengue virus | DENV-2 replicon | | Luciferase reporter assay | Decrease (90 %) | Approved | 28814523 |
| DrugRepV_5750 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Dengue virus | DENV-2 replicon | | Luciferase reporter assay | Decrease (100 %) | Approved | 28814523 |
| DrugRepV_5768 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Plaque assay | Decrease (89 %) | Experimental | 25251726 |
| DrugRepV_5769 | Digitoxin | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Plaque assay | Decrease (94 %) | Approved | 25251726 |
| DrugRepV_5770 | Digoxin | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Plaque assay | Decrease (92 %) | Approved | 25251726 |
| DrugRepV_5776 | Mephentermine sulphate | Cardiovascular agents | Hypotension | Dengue virus | Singapore isolates | | Plaque assay | Decrease (75 %) | Approved | 25251726 |
| DrugRepV_5784 | Mexiletine Hydrochloride | Cardiovascular agents | Ventricular tachycardia | Symptomatic premature ventricular beats | Dengue virus | Singapore isolates | | Plaque assay | Decrease (65 %) | NA | 25251726 |
| DrugRepV_5786 | Candesartan cilexetil | Cardiovascular agents | Hypertension | Dengue virus | Singapore isolates | | Plaque assay | Decrease (63 %) | Approved | 25251726 |
| DrugRepV_5788 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Plaque assay | Decrease (50 %) | Experimental | 25251726 |
| DrugRepV_5789 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Plaque assay | Decrease (50 %) | Experimental | 25251726 |
| DrugRepV_5790 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Plaque assay | Decrease (50 %) | Experimental | 25251726 |
| DrugRepV_5791 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Plaque assay | Decrease (90 %) | Experimental | 25251726 |
| DrugRepV_5792 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates (+) | | Real-time PCR | Decrease (2 Logs) | Experimental | 25251726 |
| DrugRepV_5793 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates (-) | | Real-time PCR | Decrease (2 Logs) | Experimental | 25251726 |
| DrugRepV_5794 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Western blot | Decrease (6.7 Fold) | Experimental | 25251726 |
| DrugRepV_5795 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Western blot | Decrease (6.3 Fold) | Experimental | 25251726 |
| DrugRepV_5796 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Plaque assay | Decrease (86.4 %) | Experimental | 25251726 |
| DrugRepV_5797 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Plaque assay | Decrease (95.14 %) | Experimental | 25251726 |
| DrugRepV_5798 | Lanatoside C | Cardiovascular agents | Arrhythmia | Dengue virus | Singapore isolates | | Plaque assay | Decrease (73.79 %) | Experimental | 25251726 |
| DrugRepV_5820 | Epigallocatechin Gallate | Cardiovascular agents | Hypertension and Diabetic Nephropathy | Dengue virus | NA | | Immunoflourescence assay | Decrease (50.92 %) | Phase I | 22155902 |
| DrugRepV_6333 | Epigallocatechin Gallate | Cardiovascular agents | Hypertension and Diabetic Nephropathy | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (50.92 %) | Phase I | 22155902 |
| DrugRepV_6473 | Epigallocatechin Gallate | Cardiovascular agents | Hypertension and Diabetic Nephropathy | Dengue virus | NA | | Plaque assay | Decrease | Investigational | 28744282 |
| DrugRepV_7007 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 28814523 |
| DrugRepV_7008 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved | 28814523 |
| DrugRepV_7009 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved | 28814523 |
| DrugRepV_7012 | Lacidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 28814523 |
| DrugRepV_7016 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Plaque assay | Decrease (4 Logs) | Approved, Investigational | 28814523 |
| DrugRepV_7017 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Plaque assay | Decrease (4 Logs) | Approved | 28814523 |
| DrugRepV_7018 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Plaque assay | Decrease (4 Logs) | Approved | 28814523 |
| DrugRepV_7021 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Real-time PCR | Decrease (0.01 %) | Approved, Investigational | 28814523 |
| DrugRepV_7022 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Real-time PCR | Decrease (0.01 %) | Approved | 28814523 |
| DrugRepV_7023 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Real-time PCR | Decrease (0.01 %) | Approved | 28814523 |
| DrugRepV_7026 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_7027 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (100 %) | Approved | 28814523 |
| DrugRepV_7028 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (100 %) | Approved | 28814523 |
| DrugRepV_7031 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (99 %) | Approved, Investigational | 28814523 |
| DrugRepV_7032 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (98 %) | Approved | 28814523 |
| DrugRepV_7033 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (96 %) | Approved | 28814523 |
| DrugRepV_7036 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (65 %) | Approved, Investigational | 28814523 |
| DrugRepV_7037 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (90 %) | Approved | 28814523 |
| DrugRepV_7038 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (95 %) | Approved | 28814523 |
| DrugRepV_7041 | Manidipine | Cardiovascular agents | Hypertension | West Nile virus | WNV replicon | | Luciferase reporter assay | Decrease (55 %) | Approved, Investigational | 28814523 |
| DrugRepV_7042 | Cilnidipine | Cardiovascular agents | Hypertension | West Nile virus | WNV replicon | | Luciferase reporter assay | Decrease (90 %) | Approved | 28814523 |
| DrugRepV_7043 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | West Nile virus | WNV replicon | | Luciferase reporter assay | Decrease (90 %) | Approved | 28814523 |
| DrugRepV_7046 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (45 %) | Approved | 28814523 |
| DrugRepV_7050 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (35 %) | Approved | 28814523 |
| DrugRepV_7054 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Survival assay | No significant effect | Approved, Investigational | 28814523 |
| DrugRepV_7055 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Plaque assay | No significant effect | Approved, Investigational | 28814523 |
| DrugRepV_7100 | Cerivastatin | Cardiovascular agents | Rhabdomyolysis | Yellow fever virus | 17D | | Plaque assay | No significant effect (No significant effect Log) | Approved | 26752081 |
| DrugRepV_7336 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | P3 | | Plaque assay | Decrease (2 log %) | Investigational | 24348901 |
| DrugRepV_7339 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | P3 | | Immunoflourescence assay | Decrease (60 %) | Investigational | 24348901 |
| DrugRepV_7342 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | P3 | | Luminescence assay | Decrease (50 %) | Investigational | 24348901 |
| DrugRepV_7394 | Epigallocatechin Gallate | Cardiovascular agents | Hypertension and Diabetic Nephropathy | West Nile virus | NY-99 | | Plaque assay | Decrease (1.1 Log) | Investigational | 28744282 |
| DrugRepV_7396 | Epigallocatechin Gallate | Cardiovascular agents | Hypertension and Diabetic Nephropathy | West Nile virus | NY-99 | | RT-PCR | Decrease (0.7 Copies/cell) | Investigational | 28744282 |
| DrugRepV_7538 | Digoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7539 | Digoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7540 | Digitoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7541 | Digitoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7678 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved, Investigational | 32577649 |
| DrugRepV_7692 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7897 | Ouabain | Cardiovascular agents | Atrial fibrillation and flutter | Heart failure | Japanese encephalitis virus | NA | | NA | Decrease (50 %) | Approved | 31871089 |
| DrugRepV_7898 | Digoxin | Cardiovascular agents | Arrhythmia | Japanese encephalitis virus | NA | | NA | Decrease (50 %) | Approved | 31871089 |
| DrugRepV_8176 | Atorvastatin Calcium | Cardiovascular agents | Coronary heart disease | Vaccinia virus | NA | | NA | Decrease (25.4 %) | Approved | 32708182 |
| DrugRepV_8275 | Digoxin | Cardiovascular agents | Arrhythmia | Zika virus | NA | NA | qRT-PCR | Decrease (50 %) | Approved | 32669655 |
| DrugRepV_8276 | Ouabain | Cardiovascular agents | Atrial fibrillation and flutter | Heart failure | Zika virus | NA | NA | qRT-PCR | Decrease (50 %) | Approved | 32669655 |